UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorp ...

Dare Bioscience, Inc. (NASDAQ:DARE) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and Chief Executive Officer John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Zegbah Jallah - ROTH Capital Partners Douglas Tsao - H.C. Wainwright Kumaraguru Raja - Brookline Capital Markets Operator Welcome to the conference call hosted by Dare Bioscience to review the company's financial results f ...

Financial Performance - Net loss for the three months ended March 31, 2022, was $8,398,670, compared to a net loss of $7,323,644 for the same period in 2021, indicating an increase in loss of about 14.7%[14] - Total operating expenses for the three months ended March 31, 2022, were $8,400,449, up from $7,693,534 in the same period of 2021, marking an increase of approximately 9.2%[14] - The company reported a loss per common share of $0.10 for the three months ended March 31, 2022, compared to a loss per common share of $0.16 for the same period in 2021[14] - For the three months ended March 31, 2022, the company incurred a net loss of approximately $8.4 million, compared to a net loss of approximately $7.3 million for the same period in 2021[32] - The company reported negative cash flow from operations of approximately $12.3 million for the three months ended March 31, 2022, an increase from negative cash flow of approximately $8.4 million in the prior year[32] Assets and Liabilities - Total current assets decreased from $55,296,016 as of December 31, 2021, to $47,817,188 as of March 31, 2022, representing a decline of approximately 13.4%[12] - Total liabilities increased from $17,052,856 as of December 31, 2021, to $18,307,672 as of March 31, 2022, reflecting a rise of approximately 7.4%[12] - Cash and cash equivalents decreased from $51,674,087 as of December 31, 2021, to $39,316,911 as of March 31, 2022, a reduction of about 23.9%[12] - The accumulated deficit increased from $110,126,902 as of December 31, 2021, to $118,525,572 as of March 31, 2022, representing a rise of about 7.8%[12] - Total stockholders' equity decreased from $38,754,321 as of December 31, 2021, to $30,878,910 as of March 31, 2022, a decline of about 20.4%[12] Shareholder Information - The weighted average number of common shares outstanding increased from 44,502,582 for the three months ended March 31, 2021, to 83,944,119 for the same period in 2022, indicating a significant increase of approximately 88.5%[14] - As of March 31, 2022, the Company had outstanding warrants for 1,374,515 shares at an exercise price of $0.96, expiring on February 15, 2023[99] - The Company has approximately 27 million authorized shares of common stock available for issuance as of the date of the report[36] Research and Development - Research and development expenses for the three months ended March 31, 2022, were $5,805,462, slightly up from $5,728,206 in the same period of 2021, reflecting an increase of approximately 1.4%[14] - The company expects significant increases in research and development expenses in 2022 compared to 2021 as it continues to develop its product candidates[34] - The Company has not generated any revenue to date and primarily focuses on research and development activities[25] Licensing and Collaboration Agreements - The Company entered into an exclusive license agreement with Organon, receiving a non-refundable upfront payment of $10.0 million and potential milestone payments up to $182.5 million[52][53][54] - The royalty payments from Organon will be tiered double-digit percentages based on net sales, continuing until the expiration of patent claims or 10 years after the first commercial sale in each country[54][55] - The license agreement with Bayer includes a $1.0 million upfront payment and potential milestone payments totaling up to $310.0 million based on sales achievements[59][61] - The Company has a strategic agreement with Hammock Pharmaceuticals, involving milestone payments up to $1.1 million for clinical and regulatory achievements[64][66] - The Company has incurred $235,000 in license fees payable to MilanaPharm, with additional milestone payments based on commercial sales[64][66] Financial Obligations and Future Funding - The Company anticipates needing to raise substantial additional capital to fund its operations and execute its current strategy[36] - The Company is committed to a total of $5.5 million in payments to NICHD for the Ovaprene Phase 3 study, with $5.0 million already paid as of March 31, 2022[111] - The Company agreed to pay up to $46.5 million in contingent consideration to former MBI stockholders based on achieving specific milestones, with $1.25 million already payable as of June 2021[112] Grants and Non-Dilutive Funding - The Company received approximately $1.9 million in non-dilutive grant funding from NICHD for Ovaprene development from 2018 to 2021[116] - A grant of $300,000 was awarded by NICHD for the development of DARE-PTB1, with potential additional funding of up to $2.0 million contingent on Phase I results[117] - The Company entered into a new grant agreement with the Foundation in June 2021 for up to $48.95 million to support DARE-LARC1 development, with an initial payment of $11.45 million received in July 2021[121] Acquisitions - The Company acquired Dare MB Inc. for $2.4 million, issuing approximately 3.0 million shares valued at $0.79 per share, to develop a long-acting reversible contraception method[86] - The Company completed the acquisition of Pear Tree Pharmaceuticals to develop a proprietary vaginal formulation of tamoxifen, with contingent payments based on clinical, regulatory, and commercial milestones[89] Clinical Studies - The Company commenced a Phase 1/2 clinical study of DARE-HRT1 in April 2022, evaluating pharmacokinetics in approximately 20 healthy, postmenopausal women[124]

Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2021 Earnings Conference Call March 31, 2022 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer Lisa Walters-Hoffert – Chief Financial Officer John Fair – Chief Strategy Officer Conference Call Participants Zegbah Jallah – ROTH Capital Partners, LLC Douglas Tsao – H.C. Wainwright & Co. Kumaraguru Raja – Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to review the company's financ ...

UNITED STATES ☒ For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO_____ | --- | --- | |-------|-----------------------------------------------------------------------------------------------------------------| | | SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ | | | FORM 10-K _____________________________________________ ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - CFO Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Chris Bialas – H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the Company’s Financial Results for the Quarter Ended September 30, 2021, and to provide a General Business Upda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - CSO Lisa Walters-Hoffert - CFO Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Doug Tsao - H. C. Wainwright Kumar Raja - Brookline Capital Markets Operator Thank you all for standing-by. And welcome to the conference call hosted by Daré Bioscience to review the Company’s Financial Results for the Quarter Ended June 30 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. 001-3 ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer John Fair – Chief Strategy Officer Lisa Walters-Hoffert – Chief Financial Officer Conference Call Participants Zegbeh Jallah – ROTH Capital Partners Chris Bialas – H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the Company’s Financial Results for the Quarter Ended March 31, 2021, and to ...